Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:04:45 ON 11 OCT 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:04:58 ON 11 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1
DICTIONARY FILE UPDATES: 10 OCT 2007 HIGHEST RN 950149-06-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10574652.str





chain nodes :
16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
1-19 2-20 8-10 11-16 16-17 16-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :
1-19 2-20 5-7 6-9 7-8 8-9 10-14 11-12 11-16
exact bonds :
8-10 10-11 12-13 13-14 16-17 16-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 10 :

G1:O,X

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,X

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:05:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 159 TO 721
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:05:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 580 TO ITERATE

100.0% PROCESSED 580 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

L3 5 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 07:05:28 ON 11 OCT 2007

FILE COVERS 1907 - 11 Oct 2007 VOL 147 ISS 16
FILE LAST UPDATED: 10 Oct 2007 (20071010/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3 full
L4           1 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:346805 CAPLUS
DOCUMENT NUMBER: 142:392411
TITLE: Preparation of 1,6,7-trisubstituted azabenzimidazoles as Rho-kinase inhibitors
INVENTOR(S): Lee, Dennis; Stavenger, Robert A.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034866	A2	20050421	WO 2004-US32909	20041006
WO 2005034866	A3	20050728		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1670466	A2	20060621	EP 2004-794310	20041006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007507549	T	20070329	JP 2006-534285	20041006
US 2007004771	A1	20070104	US 2006-574652	20060404
PRIORITY APPLN. INFO.:			US 2003-509123P P	20031006
			WO 2004-US32909 W	20041006

OTHER SOURCE(S): CASREACT 142:392411; MARPAT 142:392411
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of novel azabenzimidazoles I, which are inhibitors of Rho-kinases. In compds. I, R1 is H or C1-6 alkyl; R2 is halo or optionally substituted Ph, heteroaryl, or carboxamide; R3 is halo, (un)substituted C1-6 alkoxy, (un)substituted phenoxy, heteroaryloxy, or heterocyclyloxy. The invention also relates to the preparation of I, pharmaceutical compns. containing I as active ingredients, as well as to the use of the compns. for the treatment of disorders involving Rho-kinases. II, prepared by bromination of 3-nitro-4-pyridone followed by chlorination, was oxidized to the corresponding 2-pyridone, which was chlorinated and substituted with ethylamine to give III, which underwent substitution with 4-fluorophenol, reduction, and cyclization with cyanoacetic acid to form IV. Nitrous acid resulted in the transformation of IV into an oxime, which, upon heterocyclization with hydroxylamine, gave the aminofurazan-containing structure V. The compds. of the invention were tested for their inhibition of Rho-kinases (no data).
IT 850180-91-5P, (S)-4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine
850180-93-7P, 1,1-Dimethylethyl [3-[[2-(4-aminofurazan-3-yl)-7-

bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]carbamate 850180-94-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of trisubstituted azabenzimidazoles as Rho-kinase inhibitors)

RN 850180-91-5 CAPLUS
CN 3-Pyrrolidinamine, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850180-93-7 CAPLUS
CN Carbamic acid, [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850180-94-8 CAPLUS
CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)



IT 850180-88-0P, 4-[7-Bromo-1-ethyl-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850180-92-6P,

2-(4-Aminofurazan-3-yl)-1-ethyl-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridine-7-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of trisubstituted azabenzimidazoles as Rho-kinase inhibitors)

RN 850180-88-0 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-1-ethyl-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850180-92-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-fluorophenoxy)- (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 07:04:45 ON 11 OCT 2007)

     FILE 'REGISTRY' ENTERED AT 07:04:58 ON 11 OCT 2007
L1             STRUCTURE UPLOADED
L2           1 S L1
L3           5 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 07:05:28 ON 11 OCT 2007
L4           1 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.74     178.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.78      -0.78

STN INTERNATIONAL LOGOFF AT 07:05:57 ON 11 OCT 2007
```